Drugs / palmitoleate-rich oil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03372733 | Jul 2018 → Jul 2026 overdue | cardiovascular disorder | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | palmitoleate-rich oil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03372733 ↗ |
| Known as | PLO | “palmitoleate-rich oil (PLO)” NCT03372733 ↗ |
| Route | Oral | “2 capsules, 2 times a day after meals in a total of 4 capsules a day” NCT03372733 ↗ |